Yeast Virus-Derived Stimulator of the Innate Immune System Augments the Efficacy of Virus Vector-Based Immunotherapy

Supplemental material

Files in this Data Supplement:

• Supplemental file 1 -

  Fig. S1 (Specificity of each HEK293-hTLR-luc cell line.)

  Fig. S2 (HEK-293 cells, “naturally” TLR3-positive, stably transfected with NF-κB-inducible luciferase expression plasmid.)

  Fig. S3 (NAB2+Lipofectin, NAB2, or Lipofectin was tested in all HEK-hTLR cell lines in dose-response experiments.)

  Fig. S4 (RT-PCR on total RNA selected from all HEK-TLR-luc clones and HEK-293 cells.)

  Fig. S5 (NAB2 and NAB2+Lipofectin were tested for their capacity to stimulate human plasmacytoid dendritic cells.)

  Fig. S6 (Determination of suboptimal dose of MVATG9931.)

  Fig. S7 (Effect of injection schedule.)

  Fig. S8 (Extra- and intracellular presence of TLR3 in HEK-hTLR3-luc cells.)

  Sequence Alignment S1.

  PDF, 618K